iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

iPAAC Structure and the legacy of CanCon

Tit Albreht, MD, PhD, Scientific Co-ordinator of iPAAC, NIJZ,
e-mail: tit.albreht@nijz.si

Co-funded by
the Health Programme
of the European Union

The main deliverables of CanCon

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

1. European Guide on Quality Improvement in Comprehensive Cancer Control
2. Policy papers:
   a. A Public Health Genomics approach to “omics” in oncology
   b. Common European objectives for National Cancer Control Programmes (NCCPs)
   c. An impact evaluation system for the effectiveness of cancer prevention
   d. Enhancing value of cancer care to assess prevention outcomes
   e. Equity mainstreaming in cancer control in Europe

Co-funded by
the Health Programme
of the European Union

Definition elements from the Joint Action CanCon

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

- A CCCN consists of multiple units belonging to different institutions dedicated to research, prevention, diagnosis, treatment, follow-up, supportive and palliative care and rehabilitation for the benefit of cancer patients and cancer survivors.
- These units interact and have a formal agreement to work together in a programmatic and structured way with common governance, in order to pursue their goals more effectively and efficiently through collective synergies.
- Within the CCCN the care of patients is the responsibility of interprofessional teams that are multidisciplinary and tumour specific. Each team or tumour management group works together for the benefit of patients with that particular type of tumour.
- Within the CCCN all units work together and adopt uniform standards of care for cancer-specific pathways that are binding for the entire network.
- The CCCN promotes a uniform system of quality assurance; and a unified informatics system for optimal exchange of information.
- The objective of a CCCN is to provide comprehensive cancer care to all the people living in a certain geographical area, thus pursuing equality and the improvement of outcomes and quality.

Co-funded by
the Health Programme
of the European Union

Work on the CCCNs

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

- Important because of the developments in Europe
- Establishment of a definition of a CCCN
- Review of the past and ongoing experiences
- Piloting a CCCN – the success story from Czechia
- Future plans:
  - Piloting and evaluation in the new JA iPAAC
  - Accreditation of CCCNs
  - Harmonised developments considering the respectively important roles of CCCs and CCCNs

Co-funded by
the Health Programme
of the European Union

iPAAC STRUCTURE

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

Innovative Partnership for Action Against Cancer (iPAAC) is the third consecutive Joint Action dedicated to cancer control.

It is organised alongside the guidelines for such projects into WPs:

WP 1 – Coordination – National Institute of Public Health of Slovenia (NIJZ)

WP 2 – Disemination – Institute of Health Information and Statistics of the Czech Republic (UZIS)

WP 3 – Evaluation – Croatian National Institute of Public Health (HZJZ)

WP 4 – Integration in National Policies and Sustainability – Belgian Cancer Centre, Sciensano

Co-funded by
the Health Programme
of the European Union

iPAAC STRUCTURE 2.

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

WP 5 – Prevention and Screening – THL – Cancer Society of Finland (CSF)

WP 6 – Genomics in Cancer Control and Care – Belgian Cancer Centre

WP 7 – Cancer Information and Registration – Italian National Institute of Public Health - ISS

WP 8 – Challenges in Cancer Care - Catalan Institute of Oncology - ICO

WP 9 – Innovative Therapies in Cancer – French National Institute of Cancer - INCa

WP 10 –Governance of Integrated and Comprehensive Cancer Care – German Federal Ministry of Health and German Cancer Society (DKG)

Co-funded by
the Health Programme
of the European Union

iPAAC PARTNER COUNTRIES

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

Co-funded by
the Health Programme
of the European Union

GENERAL OBJECTIVE OF THE PROJECT

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

The general objective of the iPAAC Joint Action (JA) is to develop innovative approaches to advances in cancer control.

The development of innovative approaches to cancer control will be supplemented by a **Roadmap on Implementation and Sustainability of Cancer Control Actions**, which will support Member States in implementation of iPAAC and CANCON recommendations.

Co-funded by
the Health Programme
of the European Union

SPECIFIC OBJECTIVES

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

1. To develop and produce the Roadmap on Implementation and Sustainability of Cancer Control Actions
2. To reinforce prevention of cancer through further development of the European Code Against Cancer and population-based screening programmes
3. To develop a comprehensive approach to the use of genomics in cancer control and care
4. To pilot the integration of population-based cancer registry datasets with clinical and administrative data to derive key indicators on cancer care pathway and health-related costs in selected European countries or regions and to deliver informative epidemiological indicators on cancer prevalence by country in Europe

Co-funded by
the Health Programme
of the European Union

SPECIFIC OBJECTIVES 2.

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

5. To define strategies to improve the quality of cancer care by optimising the use of healthcare resources and promoting realistic and evidence-based responses to existing needs

6. To map recommendations and best practice guidelines for specific immunotherapies, to anticipate and predict impact of new specific immunotherapies before their marketed authorisation and to follow specific immunotherapies after their marketed authorisation

7. **To develop practical instruments to support Member States in successful governance of cancer care, ensuring standardised, integrated and comprehensive oncological care that is tumour-specific and delivers all-encompassing high-quality care to all patients**

Co-funded by
the Health Programme
of the European Union

iPAAC – IMPLEMENTING FOR THE FUTURE

iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

THANK YOU!

Co-funded by
the Health Programme
of the European Union